JTO Clinical and Research Reports : Impact Factor & More
eISSN: 2666-3643
Open AccessShare this on:
Key Metrics
CiteScore 
1
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on JTO Clinical and Research Reports
JTO Clinical and Research Reports Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Elsevier |
| Language | English |
| Article Processing Charges | USD 2000 |
| Publication Time | 19 |
| Editorial Review Process | Blind peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | International Association for the Study of Lung Cancer |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in JTO Clinical and Research Reports ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in JTO Clinical and Research Reports
Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry.
- 1 May 2026
- JTO clinical and research reports
Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).
- 1 May 2026
- JTO clinical and research reports
Biomarker Testing Among Non-Squamous Non-Small Cell Lung Cancer Patients Across Three Time Periods and Three Testing Platforms – A Brief Report
- 1 May 2026
- JTO Clinical and Research Reports
Paraneoplastic Brachial Amyotrophic Diplegia and Encephalitis With Ma2-IgG During Immune Checkpoint Inhibitor Use for Mesothelioma: A Case Report.
- 1 May 2026
- JTO clinical and research reports
Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma
- 1 May 2026
- JTO Clinical and Research Reports
Patient-Derived Lung Cancer Organoids for Precision Oncology: A Comprehensive Analysis.
- 1 May 2026
- JTO clinical and research reports
Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry.
- 1 May 2026
- JTO clinical and research reports
Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).
- 1 May 2026
- JTO clinical and research reports
Biomarker Testing Among Non-Squamous Non-Small Cell Lung Cancer Patients Across Three Time Periods and Three Testing Platforms – A Brief Report
- 1 May 2026
- JTO Clinical and Research Reports
Paraneoplastic Brachial Amyotrophic Diplegia and Encephalitis With Ma2-IgG During Immune Checkpoint Inhibitor Use for Mesothelioma: A Case Report.
- 1 May 2026
- JTO clinical and research reports
Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma
- 1 May 2026
- JTO Clinical and Research Reports
Patient-Derived Lung Cancer Organoids for Precision Oncology: A Comprehensive Analysis.
- 1 May 2026
- JTO clinical and research reports
FAQs on JTO Clinical and Research Reports
How many articles did JTO Clinical and Research Reports publish last year? 
What is Citescore for JTO Clinical and Research Reports?
Who is the publisher of JTO Clinical and Research Reports?
